Your session is about to expire
← Back to Search
Quadratus Lumborum Block for Pancreatic Cancer
Phase 2
Waitlist Available
Led By Ching-Wei D Tzeng
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights
Study Summary
This trial looks at whether reducing the need for opioids after surgery by using a quadratus lumborum block may help patients recover more quickly and reduce the risk of opioid dependence.
Eligible Conditions
- Pancreatic Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Participants Discharged Opioid-Free
Secondary outcome measures
Hospital Cost
MDASI-GI in Clinic Visits
Pain Prescription Dosage/Size
+6 moreSide effects data
From 2018 Phase 2 trial • 60 Patients • NCT0300796627%
Nausea
23%
Itching
17%
Vomiting
100%
80%
60%
40%
20%
0%
Study treatment Arm
Quadratus Lumborum Block
Ilioinguinal / Iliohypogastric Block
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm II (second QL block)Experimental Treatment4 Interventions
Patients undergo QL block before surgery and receive multimodal pain control. Patients then undergo a second QL block on day 4 after surgery and continue to receive standard of care.
Group II: Arm I (QL block, standard of care)Active Control4 Interventions
Patients undergo QL block before surgery and receive standard of care multimodal pain control after surgery.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Quadratus Lumborum Block
2020
Completed Phase 2
~820
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,958 Previous Clinical Trials
1,798,313 Total Patients Enrolled
Ching-Wei D TzengPrincipal InvestigatorM.D. Anderson Cancer Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger